Ensysce Biosciences, Inc. (ENSC) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2021
Loading P/E history...
ENSC Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Ensysce Biosciences, Inc. (ENSC) trades at a price-to-earnings ratio of -0.1x, with a stock price of $0.35 and trailing twelve-month earnings per share of $-3.80.
The current P/E is 100% below its 5-year average of 149819.8x. Over the past five years, ENSC's P/E has ranged from a low of 2583.8x to a high of 708953.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, ENSC trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, ENSC trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ENSC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ENSC P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 21.8Lowest | 1.22Best | -7% | |
| $911M | 144.7 | - | +107% | |
| $2B | 33.6 | 4.50 | +1883%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ENSC Historical P/E Data (2019–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $47087.64 | $3.62 | 13007.6x | -91% |
| FY2020 Q4 | $44764.92 | $17.33 | 2583.8x | -98% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $38520.00 | $14.47 | 2663.0x | -98% |
| FY2020 Q1 | $39276.00 | $0.06 | 708953.1x | +373% | |
| FY2019 Q4 | $37512.00 | $0.24 | 156104.9x | +4% | |
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $36864.00 | $0.42 | 87855.1x | -41% |
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $36612.00 | $0.41 | 89911.6x | -40% |
| FY2019 Q1 | Sun Mar 31 2019 00:00:00 GM | $36129.60 | $0.26 | 137479.5x | -8% |
Average P/E for displayed period: 149819.8x
See ENSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ENSC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonENSC — Frequently Asked Questions
Quick answers to the most common questions about buying ENSC stock.
Is ENSC stock overvalued or undervalued?
ENSC trades at -0.1x P/E, below its 5-year average of 149819.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ENSC's valuation compare to peers?
Ensysce Biosciences, Inc. P/E of -0.1x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is ENSC's PEG ratio?
ENSC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2021.